Skip to main content

Research Repository

Advanced Search

All Outputs (3)

Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? (2009)
Journal Article
Smith, L., Qutob, O., Watson, M. B., Beavis, A. W., Potts, D., Welham, K. J., …Cawkwell, L. (2009). Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?. Neoplasia, 11(11), 1194-1207. https://doi.org/10.1593/neo.09902

PURPOSE: We aimed to identify putative predictive protein biomarkers of radioresistance. EXPERIMENTAL DESIGN: Three breast cancer cell lines (MCF7, MDA-MB-231, and T47D) were used as in vitro models to study radioresistance. Inherent radiosensitiviti... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines (2009)
Journal Article
O'Kane, S. L., Eagle, G. L., Greenman, J., Lind, M. J., & Cawkwell, L. (2010). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer, 67(2), 160-165. https://doi.org/10.1016/j.lungcan.2009.04.008

BACKGROUND Although malignant pleural mesothelioma is a rare tumour, its incidence is increasing. The prognosis remains very poor with an average survival of 10 months from diagnosis. The choice of chemotherapy regimens for mesothelioma patients is l... Read More about COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study (2009)
Journal Article
Dueland, S., Aamdal, S., Lind, M. J., Thomas, H., Sandvold, M. L., Gaullier, J., & Rasch, W. (2009). Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study. Acta Oncologica, 48(1), 137-145. https://doi.org/10.1080/02841860802183620

Purpose. Cytarabine (ara-C) has limited activity in solid tumours. CP-4055 (ELACYTT) is a novel ara-C-5'-elaidic acid ester that may circumvent this limitation. CP-4055 maximum tolerated dose (MTD), pharmacokinetics and antitumor activity have been i... Read More about Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study.